NCT03332836View on ClinicalTrials.gov

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

January 30, 2019

Study Completion Date

September 30, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
BIOLOGICAL

HM12460A

HM12460A is a long-acting insulin

Trial Locations (1)

91911

Hanmi Investigative Site, Chula Vista

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT03332836 - Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter